Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats

Rachael A. Humphreys, Kathleen A. Kane, J. Parratt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It has been proposed that the cardioprotective effects of myocardial ischaemic preconditioning may involve the release of mast cell mediators. The aim of the study was to determine whether mast cells are involved in the antiarrhythmic effect of ischaemic preconditioning in rat hearts. Preconditioning was achieved, both in anaesthetised rats and in rat isolated hearts, by a 3-min temporary occlusion of the left main coronary artery followed by 10 min of reperfusion before a 30-min permanent occlusion. Preconditioning had a marked antiarrhythmic effect, reducing the number of ventricular ectopic beats from 1,176 ± 69 to 490 ± 139 and the incidence of ventricular fibrillation from 40% to 0. Administration of the mast cell- stabilising drugs lodoxamide tromethamine and sodium cromoglycate (20 mg/kg/h i.v. 30 min before and throughout experimental protocol) did not modify the antiarrhythmic effect of preconditioning. Sodium cromoglycate, but not lodoxamide tromethamine, itself significantly reduced the number of ectopic beats that occurred over a 30-min period of ischaemia (from 760 ± 181 to 153 ± 33 in nonpreconditioned animals). Both drugs abolished the decrease in arterial blood pressure that occurred on coronary artery occlusion. The decrease in arterial blood pressure produced by the mast cell-degranulating compound 48/80 (50 μg/kg; i.v.) was attenuated to a similar degree by both drugs (decreases in pressure of 53 ± 7, 31 ± 1, and 25 ± 3 mm Hg in control, sodium cromoglycate-treated, and lodoxamide tromethamine-treated animals, respectively). In rat isolated hearts, degranulation of mast cells with three consecutive doses of 50 μg of compound 48/80 had no antiarrhythmic effects and did not modify the antiarrhythmic effect of preconditioning. It is concluded that cardiac mast cells do not play a major role in the protection offered by ischaemic preconditioning on arrhythmogenesis in rat hearts.

Original languageEnglish
Pages (from-to)418-423
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume31
Issue number3
DOIs
Publication statusPublished - Mar 1998

Fingerprint

Cell Degranulation
Mast Cells
Cromolyn Sodium
p-Methoxy-N-methylphenethylamine
Ischemic Preconditioning
Coronary Vessels
Arterial Pressure
Myocardial Ischemic Preconditioning
Pharmaceutical Preparations
Ventricular Premature Complexes
Coronary Occlusion
Ventricular Fibrillation
Reperfusion
Ischemia
Pressure
Incidence
lodoxamide tromethamine

Keywords

  • Arrhythmias
  • Mast cell stabilizers
  • Mast cells
  • Preconditioning
  • Rat

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats. / Humphreys, Rachael A.; Kane, Kathleen A.; Parratt, J.

In: Journal of Cardiovascular Pharmacology, Vol. 31, No. 3, 03.1998, p. 418-423.

Research output: Contribution to journalArticle

@article{e1b24ec660ad44759fdca01c1b7cbd13,
title = "Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats",
abstract = "It has been proposed that the cardioprotective effects of myocardial ischaemic preconditioning may involve the release of mast cell mediators. The aim of the study was to determine whether mast cells are involved in the antiarrhythmic effect of ischaemic preconditioning in rat hearts. Preconditioning was achieved, both in anaesthetised rats and in rat isolated hearts, by a 3-min temporary occlusion of the left main coronary artery followed by 10 min of reperfusion before a 30-min permanent occlusion. Preconditioning had a marked antiarrhythmic effect, reducing the number of ventricular ectopic beats from 1,176 ± 69 to 490 ± 139 and the incidence of ventricular fibrillation from 40{\%} to 0. Administration of the mast cell- stabilising drugs lodoxamide tromethamine and sodium cromoglycate (20 mg/kg/h i.v. 30 min before and throughout experimental protocol) did not modify the antiarrhythmic effect of preconditioning. Sodium cromoglycate, but not lodoxamide tromethamine, itself significantly reduced the number of ectopic beats that occurred over a 30-min period of ischaemia (from 760 ± 181 to 153 ± 33 in nonpreconditioned animals). Both drugs abolished the decrease in arterial blood pressure that occurred on coronary artery occlusion. The decrease in arterial blood pressure produced by the mast cell-degranulating compound 48/80 (50 μg/kg; i.v.) was attenuated to a similar degree by both drugs (decreases in pressure of 53 ± 7, 31 ± 1, and 25 ± 3 mm Hg in control, sodium cromoglycate-treated, and lodoxamide tromethamine-treated animals, respectively). In rat isolated hearts, degranulation of mast cells with three consecutive doses of 50 μg of compound 48/80 had no antiarrhythmic effects and did not modify the antiarrhythmic effect of preconditioning. It is concluded that cardiac mast cells do not play a major role in the protection offered by ischaemic preconditioning on arrhythmogenesis in rat hearts.",
keywords = "Arrhythmias, Mast cell stabilizers, Mast cells, Preconditioning, Rat",
author = "Humphreys, {Rachael A.} and Kane, {Kathleen A.} and J. Parratt",
year = "1998",
month = "3",
doi = "10.1097/00005344-199803000-00013",
language = "English",
volume = "31",
pages = "418--423",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats

AU - Humphreys, Rachael A.

AU - Kane, Kathleen A.

AU - Parratt, J.

PY - 1998/3

Y1 - 1998/3

N2 - It has been proposed that the cardioprotective effects of myocardial ischaemic preconditioning may involve the release of mast cell mediators. The aim of the study was to determine whether mast cells are involved in the antiarrhythmic effect of ischaemic preconditioning in rat hearts. Preconditioning was achieved, both in anaesthetised rats and in rat isolated hearts, by a 3-min temporary occlusion of the left main coronary artery followed by 10 min of reperfusion before a 30-min permanent occlusion. Preconditioning had a marked antiarrhythmic effect, reducing the number of ventricular ectopic beats from 1,176 ± 69 to 490 ± 139 and the incidence of ventricular fibrillation from 40% to 0. Administration of the mast cell- stabilising drugs lodoxamide tromethamine and sodium cromoglycate (20 mg/kg/h i.v. 30 min before and throughout experimental protocol) did not modify the antiarrhythmic effect of preconditioning. Sodium cromoglycate, but not lodoxamide tromethamine, itself significantly reduced the number of ectopic beats that occurred over a 30-min period of ischaemia (from 760 ± 181 to 153 ± 33 in nonpreconditioned animals). Both drugs abolished the decrease in arterial blood pressure that occurred on coronary artery occlusion. The decrease in arterial blood pressure produced by the mast cell-degranulating compound 48/80 (50 μg/kg; i.v.) was attenuated to a similar degree by both drugs (decreases in pressure of 53 ± 7, 31 ± 1, and 25 ± 3 mm Hg in control, sodium cromoglycate-treated, and lodoxamide tromethamine-treated animals, respectively). In rat isolated hearts, degranulation of mast cells with three consecutive doses of 50 μg of compound 48/80 had no antiarrhythmic effects and did not modify the antiarrhythmic effect of preconditioning. It is concluded that cardiac mast cells do not play a major role in the protection offered by ischaemic preconditioning on arrhythmogenesis in rat hearts.

AB - It has been proposed that the cardioprotective effects of myocardial ischaemic preconditioning may involve the release of mast cell mediators. The aim of the study was to determine whether mast cells are involved in the antiarrhythmic effect of ischaemic preconditioning in rat hearts. Preconditioning was achieved, both in anaesthetised rats and in rat isolated hearts, by a 3-min temporary occlusion of the left main coronary artery followed by 10 min of reperfusion before a 30-min permanent occlusion. Preconditioning had a marked antiarrhythmic effect, reducing the number of ventricular ectopic beats from 1,176 ± 69 to 490 ± 139 and the incidence of ventricular fibrillation from 40% to 0. Administration of the mast cell- stabilising drugs lodoxamide tromethamine and sodium cromoglycate (20 mg/kg/h i.v. 30 min before and throughout experimental protocol) did not modify the antiarrhythmic effect of preconditioning. Sodium cromoglycate, but not lodoxamide tromethamine, itself significantly reduced the number of ectopic beats that occurred over a 30-min period of ischaemia (from 760 ± 181 to 153 ± 33 in nonpreconditioned animals). Both drugs abolished the decrease in arterial blood pressure that occurred on coronary artery occlusion. The decrease in arterial blood pressure produced by the mast cell-degranulating compound 48/80 (50 μg/kg; i.v.) was attenuated to a similar degree by both drugs (decreases in pressure of 53 ± 7, 31 ± 1, and 25 ± 3 mm Hg in control, sodium cromoglycate-treated, and lodoxamide tromethamine-treated animals, respectively). In rat isolated hearts, degranulation of mast cells with three consecutive doses of 50 μg of compound 48/80 had no antiarrhythmic effects and did not modify the antiarrhythmic effect of preconditioning. It is concluded that cardiac mast cells do not play a major role in the protection offered by ischaemic preconditioning on arrhythmogenesis in rat hearts.

KW - Arrhythmias

KW - Mast cell stabilizers

KW - Mast cells

KW - Preconditioning

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0031913880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031913880&partnerID=8YFLogxK

U2 - 10.1097/00005344-199803000-00013

DO - 10.1097/00005344-199803000-00013

M3 - Article

VL - 31

SP - 418

EP - 423

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -